A human xenobiotic nuclear receptor contributes to nonresponsiveness of Mycobacterium tuberculosis to the antituberculosis drug rifampicin

Abstract

Mycobacterium tuberculosis is the causative agent of tuberculosis (TB). It acquires phenotypic drug resistance inside macrophages, and this resistance mainly arises from host-induced stress. However, whether cellular drug efflux mechanisms in macrophages contribute to nonresponsiveness of M. tuberculosis to anti-TB drugs is unclear. Here, we report that xenobiotic nuclear receptors mediate TB drug nonresponsiveness by modulating drug efflux transporters in macrophages. This was evident from expression analysis of drug efflux transporters in macrophages isolated from TB patients. Among patients harboring rifampicin-susceptible M. tuberculosis, we observed increased intracellular survival of M. tuberculosis upon rifampicin treatment of macrophages isolated from patients not responding to anti-TB drugs compared with macrophages from patients who did respond. Of note, M. tuberculosis infection and rifampicin exposure synergistically modulated macrophage drug-efflux transporters in vitro. We also found that the xenobiotic nuclear receptor pregnane X receptor (PXR) modulates macrophage drug efflux transporter expression and activity, which compromised the anti-TB efficacy of rifampicin. We further validated this finding in a TB mouse model in which use of the PXR antagonist ketoconazole rescued rifampicin anti-TB activity. We conclude that PXR activation in macrophages compromises the efficacy of the anti-TB drug rifampicin. Alternative therapeutic strategies, such as use of the rifampicin derivatives rifapentine and rifabutin, which do not activate PXR, or of a PXR antagonist, may be effective for tackling drug nonresponsiveness of M. tuberculosis that arises from drug efflux systems of the host.M. tuberculosis is the primary causative agent of human TB and is responsible for maximum deaths than any other single http://www.jbc.org/cgi

Mycobacterium tuberculosis and macrophage nuclear receptors: What we do and don't know

“…In a subsequent study, the same research group showed that PXR can modulate macrophage drug-efflux transporter expression and activity, compromising the effect of rifampicin in vitro in hMDMs (Fig 2) [92]. Previous studies showed that rifampicin is a potent PXR activator that can induce expression of important metabolizing enzymes [93].…”

“…Previous studies showed that rifampicin is a potent PXR activator that can induce expression of important metabolizing enzymes [93]. In mice infected with M.tb, the PXR antagonist ketoconazole rescued the activity of rifampicin [92].…”

The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Coinfected Patients in Uganda in the SOUTH Study

“…P‐gp, for instance, is highly expressed in lung tissues and alveolar macrophages, and its expression may be more relevant for pulmonary concentrations rather than plasma levels. In human tissues and in a mouse model, PXR activation has been shown to reduce the effect of RIF . Several pathways leading to inflammatory processes have been shown to be controlled by PXR, thus potentially being variable among individuals in terms of appropriate immune response and microbe killing .…”

“…In human tissues and in a mouse model, PXR activation has been shown to reduce the effect of RIF. 35 Several pathways leading to inflammatory processes have been shown to be controlled by PXR, thus potentially being variable among individuals in terms of appropriate immune response and microbe killing. 36 The high heterogeneity in causes of death did not allow for exploring the association for specific unfavorable outcomes.…”

Host Directed Therapy Against Infection by Boosting Innate Immunity

“…One key mechanism appears to involve direct interactions between RIF and nuclear receptors. For example, it has been shown that RIF activates pregnane X receptor (PXR) that can promote TB growth in macrophages via increased efflux of TB-drugs out of the cell (123). This leads to sustained bacterial growth in the presence of the drug, which may accelerate the development of resistance.…”